Oncology Molecular Diagnostics Market to Reach US$ 6.46 Billion by 2033, Driven by Precision Oncology, and Accelerating Biomarker-Based Therapies - According to DataM Intelligence

According to DataM Intelligence AUSTIN, Texas and TOKYO, Nov. 18, 2025 /PRNewswire/ -- DataM Intelligence announces the latest insights into the rapidly transforming Oncology Molecular Diagnostics ...

Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Tr…

Largest prospective clinical trial to-date in a rare subtype of GISTROCKVILLE, Md. and SUZHOU, China, (GLOBE NEWSWIRE) -- ...

ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal ...

Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: ...
CURE

Gomekli Shows Early Activity in Pediatric Low Grade Glioma

Gomekli showed an 87% overall response rate in pediatric low-grade glioma with MAPK pathway activation, with a recommended ...
SpringerMedizin.at

Primary central nervous system tumors: future directions in systemic treatment

Primary central nervous system (CNS) tumors pose significant challenges due to their heterogeneous nature, frequently limited prognosis, and substantial impact on quality of life. Despite advances in ...